AlloEx
Phase 1Cell therapy
AlloEx is one of 117 biologic programs targeting Stroke. It is currently in Phase 1.
4
Indications
5
Total Trials
4
Active Trials
116
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
147 competitors in Stroke
#DrugCompanyPhaseTrials
1Zometa
PfizerPreclinical
Savella
AbbViePreclinical
Proamatine
TakedaPreclinical
Repatha
AmgenPreclinical
Zantac 150
CChattem
Preclinical
Periactin
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
Alka-Seltzer
AAbbott
Preclinical
Haldol
DDePuy Orthopaedics
Preclinical
AlloEx
TThe Foundation for Orthopaedics and Regenerative Medicine
Phase 1
Anticoagulant
BayerPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Stroke1 trial
Peripheral Neuropathy1 trial
Congenital Myasthenic Syndrome1 trial
Mesenchymal Stem Cell Exosome Treatment of Congenital Myasthenic Syndrome
Recruiting·TThe Foundation for Orthopaedics and Regenerative Medicine·Phase 1·NCT07226726·20 enrolled
Parkinson disease1 trial
Motor Disorders1 trial
Patients With ALS and Other Motor Discorders Will be Treated With Mesenchymal Cell Exosome Solution
Completed·TThe Foundation for Orthopaedics and Regenerative Medicine·Phase 1·NCT07105371·70 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for AlloEx. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details